The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
The 2023 nonhormone therapy position statement of The North American Menopause Society
Abstract
Objective: To update the evidence-based Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society. Methods: An advisory panel of clinicians and research experts in women’s health were selected to review and evaluate the literature published since the Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society. Topics were divided into five sections for ease of review: lifestyle; mind-body techniques; prescription therapies; dietary supplements; and acupuncture, other treatments, and technologies. The panel assessed the most current and available literature to determine whether to recommend or not recommend use based on these levels of evidence: Level I, good and consistent scientific evidence; Level II, limited or inconsistent scientific evidence, and Level III, consensus and expert opinion. Results: Evidence-based review of the literature resulted in several nonhormone options for the treatment of vasomotor symptoms. Recommended : Cognitive-behavioral therapy, clinical hypnosis, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant (Level I); oxybutynin (Levels I-II); weight loss, stellate ganglion block (Levels II-III). Not recommended : Paced respiration (Level I); supplements/herbal remedies (Levels I-II); cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation, suvorexant, soy foods and soy extracts, soy metabolite equol, cannabinoids, acupuncture, calibration of neural oscillations (Level II); chiropractic interventions, clonidine; (Levels I-III); dietary modification and pregabalin (Level III). Conclusion: Hormone therapy remains the most effective treatment for vasomotor symptoms and should be considered in menopausal women within 10 years of their final menstrual periods. For women who are not good candidates for hormone therapy because of contraindications (eg, estrogen-dependent cancers or cardiovascular disease) or personal preference, it is important for healthcare professionals to be well informed about nonhormone treatment options for reducing vasomotor symptoms that are supported by the evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
El‐Sedeek, M., Korish, A. A., & Deef, M. (2010) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2009.02474.x · Cited by 36
RetractedCumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., Yu, O., Crane, P. K., & Larson, E. B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7663 · Cited by 1,111
Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition
Avis, N. E., Crawford, S. L., Greendale, G., Bromberger, J. T., Everson-Rose, S. A., Gold, E. B., Hess, R., Joffe, H., Kravitz, H. M., Tepper, P. G., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.8063 · Cited by 1,028
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Self-citationGold, E. B., Colvin, A., Avis, N., Bromberger, J., Greendale, G. A., Powell, L., Sternfeld, B., & Matthews, K. (2006) · American Journal of Public Health · doi:10.2105/ajph.2005.066936 · Cited by 932
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
(2012) · Menopause · doi:10.1097/gme.0b013e31824b970a · Cited by 785
Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002978.pub2 · Cited by 543
Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.
Barton, D. L., Loprinzi, C. L., Quella, S. K., Sloan, J. A., Veeder, M. H., Egner, J. R., Fidler, P., Stella, P. J., Swan, D. K., Vaught, N. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.495 · Cited by 403
Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial
Bower, J. E., Crosswell, A. D., Stanton, A. L., Crespi, C. M., Winston, D., Arevalo, J., Ma, J., Cole, S. W., & Ganz, P. A. (2015) · Cancer · doi:10.1002/cncr.29194 · Cited by 390
Research works printed but not linked: 15
- 2018, Trends in oral and vaginally administered estrogen use among US women 50 years of age and older with commercial health insurance, Menopause, 25, 611, 10.1097/GME.0000000000001054 · doi:10.1097/gme.0000000000001054
- 2019, Dietary patterns and their association with menopausal symptoms: a cross-sectional study, Menopause, 26, 365, 10.1097/GME.0000000000001245 · DOI
- 2013, Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials, Gynecol Obstet Invest, 75, 255, 10.1159/000348564 · DOI
- 2010, Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients, Acta Derm Venereol, 90, 291, 10.2340/00015555-0828 · doi:10.2340/00015555-0828
- The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an Italian multicentre prospective observational study [published online ahead of print November 26, 2021], Minerva Obstet Gynecol
- 2009, Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms, Menopause, 16, 117, 10.1097/gme.0b013e3181806446 · doi:10.1097/gme.0b013e3181806446
- 1999, Fukiic and piscidic acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity of fukinolic acid, Planta Med, 65, 763, 10.1055/s-2006-960862 · doi:10.1055/s-2006-960862
- 2018, Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women, Climacteric, 21, 69, 10.1080/13697137.2017.1406913 · doi:10.1080/13697137.2017.1406913
- 2009, A clinical study on the effect of red ginseng for postmenopausal hot flushes, J Orient Obstet Gynecol, 22, 132
- 2007, Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study, Gynecol Endocrinol, 23, 117, 10.1080/09513590701200900 · doi:10.1080/09513590701200900
- 2021, The effect of Jazar supplement on quality of life and sexual function in postmenopausal women: a double-blind, randomized, placebo-controlled trial, Evid Based Complement Alternat Med, 8854182
- 2020, The maintenance effect of acupuncture on breast cancer-related menopause symptoms: a systematic review, Climacteric, 23, 130, 10.1080/13697137.2019.1664460 · doi:10.1080/13697137.2019.1664460
- 2018, Acupuncture for symptoms in menopause transition: a randomized controlled trial, Am J Obstet Gynecol, 219, 373.e1, 10.1016/j.ajog.2018.08.019 · doi:10.1016/j.ajog.2018.08.019
- 2022, Electroacupuncture for the treatment of perimenopausal syndrome: a systematic review and meta-analysis of randomized controlled trials, Acupunct Med, 40, 111, 10.1177/09645284211055742 · doi:10.1177/09645284211055742
- 2006, Retropharyngeal hematoma after stellate ganglion block: Analysis of 27 patients reported in the literature, Anesthesiology, 105, 1238, 10.1097/00000542-200612000-00024 · doi:10.1097/00000542-200612000-00024
Cited by
Rosendahl, J., Alldredge, C. T., & Haddenhorst, A. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1330238 · Cited by 56
Self-Administered Hypnosis vs Sham Hypnosis for Hot Flashes
Elkins, G., Arring, N., Morgan, G., Lorenz, T., Muniz, V., Lafferty, C., Scheffrahn, K., Alldredge, C., & Barton, D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.42537 · Cited by 8
Clinical hypnosis and cognitive behavioral therapy for hot flashes: a scoping review.
Muñiz, V., Padilla, V. J., Alldredge, C. T., & Elkins, G. (2025) · Women's Health Reports · doi:10.1089/whr.2024.0144 · Cited by 6
Vallée, A., & Ayoubi, J.-M. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109043 · Cited by 1
Metadata
- Venue
- Menopause
- Published
- 2023-06
- Volume
- 30
- Issue
- 6
- Pages
- 573-590
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W4378744965
- Cited by
- 309
- References
- 179
- FWCI
- 51.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The 2023 nonhormone therapy position statement of The North American Menopause Society. https://app.cochat.ai/papers/10.1097/gme.0000000000002200
- The paper
- The 2023 nonhormone therapy position statement of The North American Menopause Society. (2023). Menopause. https://doi.org/10.1097/gme.0000000000002200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.